Jade Biosciences, Inc. - Asset Resilience Ratio
Jade Biosciences, Inc. (JBIO) has an Asset Resilience Ratio of 74.97% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Jade Biosciences, Inc. to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Jade Biosciences, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Jade Biosciences, Inc..
Liquid Assets Composition Over Time
This chart breaks down Jade Biosciences, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read JBIO liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $353.95 Million | 74.97% |
| Total Liquid Assets | $353.95 Million | 74.97% |
Asset Resilience Insights
- Very High Liquidity: Jade Biosciences, Inc. maintains exceptional liquid asset reserves at 74.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jade Biosciences, Inc. Industry Peers by Asset Resilience Ratio
Compare Jade Biosciences, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA |
Biotechnology | 64.92% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 78.22% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Jade Biosciences, Inc. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Jade Biosciences, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.82% | $247.72 Million | $349.78 Million | +14.96pp |
| 2024-12-31 | 55.86% | $44.87 Million | $80.33 Million | -21.80pp |
| 2023-12-31 | 77.66% | $98.95 Million | $127.42 Million | -1.30pp |
| 2022-12-31 | 78.95% | $106.82 Million | $135.30 Million | +14.41pp |
| 2021-12-31 | 64.54% | $113.18 Million | $175.36 Million | -- |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more